Description:
The bill would Require prescription drug manufacturers to provide information to the Secretary of Health and Human Services (HHS) about the factors (including expenditure and revenue items) that contribute to increases in drug prices that exceed thresholds established in the bill Require drug manufacturers to disclose information about samples provided to physicians Direct the Secretary of HHS to study spending on drugs furnished in hospitals and to publish data about prices and discounts under Medicare Part D Require drug manufacturers to report the sales prices used to calculate payments for drugs covered under Medicare Part B Estimated budgetary effects would primarily stem from Requiring drug manufacturers to report prices used to calculate Medicare payment rates for their products administered in physicians’ offices and hospital outpatient departments Appropriating $3 million to the Secretary of HHS to study hospitals’ drug costs Areas of significant uncertainty include accurately projecting The ways that new disclosure requirements would affect the behavior of drug manufacturers or medical providers Drug manufacturers’ responses to possible changes in the regulatory status of certain products
